Mirja Thomsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mirja Thomsen has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Katja Lohmann
Institute of Neurogenetics, University of Luebeck, Luebeck, Germany
4 shared publications Christine Klein
Institute of Neurogenetics University Hospital Schleswig‐Holstein and University of Lübeck Lübeck Germany
3 shared publicationsNorbert Brüggemann
Institute of Neurogenetics University Hospital Schleswig‐Holstein and University of Lübeck Lübeck Germany
3 shared publications- Ai Huey Tan
Division of Neurology, Department of Medicine Faculty of Medicine, University of Malaya Kuala Lumpur Malaysia
2 shared publications Frauke Hinrichs
Institute of Neurogenetics University Hospital Schleswig‐Holstein and University of Lübeck Lübeck Germany
2 shared publicationsHauke Busch
Medical Systems Biology Division, Institute of Experimental Dermatology University of Lübeck Lübeck Germany
2 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Wiley in Movement Disorders
Transcriptome‐Based Identification of ZZEF1 and ENTPD5 as Candidate Genes for Dystonia
- 8 September 2026
- Published by Wiley in Movement Disorders
Open AccessTranscriptome‐Based Identification of ZZEF1 and ENTPD5 as Candidate Genes for Dystonia
- 17 July 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (9) , 2538-2540
Beyond Ocular Malformations: RARB Variants Presenting as Isolated Pediatric Movement Disorder
- 17 July 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (9) , 2538-2540
Beyond Ocular Malformations: RARB Variants Presenting as Isolated Pediatric Movement Disorder
- 9 April 2026
- Published by Oxford University Press (OUP) in Brain
DRD1-driven infantile dystonia: towards a mechanism-informed framework for GPCR receptoropathies
Despite remarkable advances in human genomics, most rare disorders remain undiagnosed, mechanistically obscure and without effective treatments. In this study, we establish DRD1, encoding the dopamine D1 receptor (D1R), as a monogenic cause of an infantile-onset dystonia syndrome, for which pharmacological responsiveness may vary depending on the underlying molecular mechanism. Across three unrelated families, eight affected individuals exhibited generalized dystonia, axial hypotonia and cognitive impairment, and carried homozygous pathogenic missense DRD1 variants. Live-cell biosensor assays revealed that patient-derived DRD1 variants disrupt receptor integrity through mechanistically diverse failures, such as trafficking deficits and impaired agonist-induced activation—ultimately converging on a collapse of D1R-mediated signalling. In line with standard clinical practice and informed by these mechanistic insights, we initiated a trial of levodopa/carbidopa in two individuals in the index family with a partial-loss-of-function variant, which was associated with improvement in voluntary motor function and cognitive engagement. Moreover, in live-cell assays, we demonstrated that Mevidalen—a selective DRD1-positive allosteric modulator currently in clinical development—substantially improved signalling in patient-derived mutants in vitro, supporting a potential future mechanism-aligned therapeutic avenue. To broaden the clinical implications of our findings, we performed a structural interpretation of DRD1 variation in 807 162 individuals and identified 29 rare predicted deleterious missense variants in heterozygous carriers. These variants clustered within evolutionarily conserved transmembrane domains and signalling motifs, providing a basis for pathogenicity assignment and variant prioritization in clinical and research settings. Building on these insights, we developed a structure-informed pharmacological experimental framework that stratifies DRD1 variants according to molecular dysfunction and matches them with mechanistically aligned therapeutic strategies—namely, orthosteric agonists, pharmacological chaperones, allosteric modulators and readthrough compounds. This in vitro approach enabled functional rescue of otherwise intractable variants, suggesting a potentially actionable molecular architecture across diverse genotypes, which remains to be tested clinically. Together, these findings identify biallelic DRD1 variants as a cause of infantile dystonia and support the potential for mechanism-informed therapeutic exploration, while emphasizing that clinical responsiveness may vary across individuals. More broadly, our integrated genomics–structure–pharmacology framework provides a proof-of-concept approach to functionally stratify G protein-coupled receptor variants, exemplified here by DRD1, and prioritize testable, mechanism-based therapeutic hypotheses for future evaluation.
- 9 April 2026
- Published by Oxford University Press (OUP) in Brain
DRD1-driven infantile dystonia: towards a mechanism-informed framework for GPCR receptoropathies
Despite remarkable advances in human genomics, most rare disorders remain undiagnosed, mechanistically obscure and without effective treatments. In this study, we establish DRD1, encoding the dopamine D1 receptor (D1R), as a monogenic cause of an infantile-onset dystonia syndrome, for which pharmacological responsiveness may vary depending on the underlying molecular mechanism. Across three unrelated families, eight affected individuals exhibited generalized dystonia, axial hypotonia and cognitive impairment, and carried homozygous pathogenic missense DRD1 variants. Live-cell biosensor assays revealed that patient-derived DRD1 variants disrupt receptor integrity through mechanistically diverse failures, such as trafficking deficits and impaired agonist-induced activation—ultimately converging on a collapse of D1R-mediated signalling. In line with standard clinical practice and informed by these mechanistic insights, we initiated a trial of levodopa/carbidopa in two individuals in the index family with a partial-loss-of-function variant, which was associated with improvement in voluntary motor function and cognitive engagement. Moreover, in live-cell assays, we demonstrated that Mevidalen—a selective DRD1-positive allosteric modulator currently in clinical development—substantially improved signalling in patient-derived mutants in vitro, supporting a potential future mechanism-aligned therapeutic avenue. To broaden the clinical implications of our findings, we performed a structural interpretation of DRD1 variation in 807 162 individuals and identified 29 rare predicted deleterious missense variants in heterozygous carriers. These variants clustered within evolutionarily conserved transmembrane domains and signalling motifs, providing a basis for pathogenicity assignment and variant prioritization in clinical and research settings. Building on these insights, we developed a structure-informed pharmacological experimental framework that stratifies DRD1 variants according to molecular dysfunction and matches them with mechanistically aligned therapeutic strategies—namely, orthosteric agonists, pharmacological chaperones, allosteric modulators and readthrough compounds. This in vitro approach enabled functional rescue of otherwise intractable variants, suggesting a potentially actionable molecular architecture across diverse genotypes, which remains to be tested clinically. Together, these findings identify biallelic DRD1 variants as a cause of infantile dystonia and support the potential for mechanism-informed therapeutic exploration, while emphasizing that clinical responsiveness may vary across individuals. More broadly, our integrated genomics–structure–pharmacology framework provides a proof-of-concept approach to functionally stratify G protein-coupled receptor variants, exemplified here by DRD1, and prioritize testable, mechanism-based therapeutic hypotheses for future evaluation.
- Top Cited PapersOpen Access
- 18 June 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (8) , 1648-1659
Genetic Diversity and Expanded Phenotypes in Dystonia: Insights From Large‐Scale Exome Sequencing
Objective: Dystonia is one of the most prevalent movement disorders, characterized by significant clinical and etiological heterogeneity. Despite considerable heritability (~25%), the etiology in most patients remains elusive. Moreover, understanding correlations between clinical manifestations and genetic variants has become increasingly complex.Methods: Exome sequencing was conducted on 1924 genetically unsolved, mainly late‐onset isolated dystonia patients, recruited primarily from two dystonia registries (DysTract and the Dystonia Coalition). Rare variants in genes previously linked to dystonia (n = 406) were examined, confirmed via Sanger sequencing, and analyzed for segregation when possible.Results: We identified 137 distinct likely pathogenic/pathogenic variants (according to ACMG criteria) across 51 genes in 163/1924 patients, including 153/1895 index patients (diagnostic yield 8.1%). The strongest predictors of a genetic diagnosis were generalized dystonia (28.6% yield) and age at onset (20.4% yield in patients with onset < 30 years). Notably, 56.2% of these variants were novel, with recurrent variants in EIF2AK2, VPS16, KCNMA1, and SLC2A1. Additionally, 321 index patients (16.9%) harbored variants of uncertain significance in 102 genes. The most frequently implicated genes included VPS16, THAP1, GCH1, SGCE, GNAL, and KMT2B. Presumably pathogenic variants in less well‐established dystonia genes were also found, including KCNMA1, KIF1A, and ZMYND11. At least six variants (in ADCY5, GNB1, IR2BPL, KCNN2, KMT2B, and VPS16) occurred de novo, supporting pathogenicity.Interpretation: This study provides valuable insights into the genetic landscape of dystonia, underscores the utility of exome sequencing for diagnosis, substantiates several candidate genes, and expands the phenotypic spectrum of some genes to include prominent, sometimes isolated dystonia.
- 18 June 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (8) , 1648-1659
Top Cited PapersOpen AccessGenetic Diversity and Expanded Phenotypes in Dystonia: Insights From Large‐Scale Exome Sequencing
Objective: Dystonia is one of the most prevalent movement disorders, characterized by significant clinical and etiological heterogeneity. Despite considerable heritability (~25%), the etiology in most patients remains elusive. Moreover, understanding correlations between clinical manifestations and genetic variants has become increasingly complex.Methods: Exome sequencing was conducted on 1924 genetically unsolved, mainly late‐onset isolated dystonia patients, recruited primarily from two dystonia registries (DysTract and the Dystonia Coalition). Rare variants in genes previously linked to dystonia (n = 406) were examined, confirmed via Sanger sequencing, and analyzed for segregation when possible.Results: We identified 137 distinct likely pathogenic/pathogenic variants (according to ACMG criteria) across 51 genes in 163/1924 patients, including 153/1895 index patients (diagnostic yield 8.1%). The strongest predictors of a genetic diagnosis were generalized dystonia (28.6% yield) and age at onset (20.4% yield in patients with onset < 30 years). Notably, 56.2% of these variants were novel, with recurrent variants in EIF2AK2, VPS16, KCNMA1, and SLC2A1. Additionally, 321 index patients (16.9%) harbored variants of uncertain significance in 102 genes. The most frequently implicated genes included VPS16, THAP1, GCH1, SGCE, GNAL, and KMT2B. Presumably pathogenic variants in less well‐established dystonia genes were also found, including KCNMA1, KIF1A, and ZMYND11. At least six variants (in ADCY5, GNB1, IR2BPL, KCNN2, KMT2B, and VPS16) occurred de novo, supporting pathogenicity.Interpretation: This study provides valuable insights into the genetic landscape of dystonia, underscores the utility of exome sequencing for diagnosis, substantiates several candidate genes, and expands the phenotypic spectrum of some genes to include prominent, sometimes isolated dystonia.
- Open Access
- 17 May 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (11) , 4072-4083
FGF14 repeat length and mosaic interruptions: modifiers of spinocerebellar ataxia 27B?
Deep intronic FGF14 repeat expansions have been identified as a frequent genetic cause of late-onset cerebellar ataxias, explaining ≤30% of patients. Interruptions between repeats have previously been identified to impact the penetrance in other repeat expansion disorders. Repeat interruptions within FGF14 have yet to be characterized in detail. We used long-range PCR, Sanger sequencing, repeat-primed PCR, Nanopore and PacBio sequencing to distinguish the repeat motifs, mosaicism and number of repeat interruptions present in FGF14-related ataxia patients and unaffected individuals. A total of 304 patients with late-onset ataxia and 190 unaffected individuals were previously screened for repeat expansions in FGF14 by long-range PCR, identifying 37 individuals with expanded repeat lengths (≥250 repeats). These, along with three newly identified expansion carriers were included in the present study, and advanced genetic methods were applied to investigate the repeat composition in 27 patients and 13 unaffected individuals. The expansions, based on Nanopore data, ranged from 236 to 486 repeats (standard deviation = 60), with 20 individuals showing repeat interruptions, including complex motifs such as GAG, GAAGGA, GAAGAAAGAA, GAAAAGAAGAAGGAAGAAGGAA, GAAAAGAAGAAGGAA and GCAGAAGAAGAAGAA. We calculated the longest pure GAA length from the long-read data for all 40 individuals. When comparing the pure GAA tract between patients and unaffected individuals, clusters were apparent based on >200 or <200 repeats. Five ataxia patients with interruptions still had a remaining pure GAA expansion <200. We observed an association of the pure GAA length with age at onset (P = 0.016, R2 = 0.256). Somatically incurred mosaic divergent repeat interruptions were discovered that affect motif length and sequence (mDRILS), which varied in number and mosaicism (frequency: 0.37–0.93). The mDRILS were correlated with pure GAA length (P = 0.022, R2 = 0.334), with a higher mosaic frequency of interruptions in unaffected individuals compared with patients (unaffected: 0.90; patients: 0.67; P = 0.009). We demonstrate that: (i) long-read sequencing is required to detect complex repeat interruptions accurately; (ii) repeat interruptions in FGF14 are mosaic, have various lengths and start positions in the repeat tract, and can thereby be annotated as mDRILS; which (iii) enabled us to establish a categorization based on remaining pure GAA repeats quantifying the impact of mDRILS on pathogenicity or age at onset, dependent on the interruption length and position, with high accuracy; and (iv) we provide evidence that mosaicism stabilizes pure GAA repeats in interrupted FGF14 repeat expansions.
- 17 May 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (11) , 4072-4083
Open AccessFGF14 repeat length and mosaic interruptions: modifiers of spinocerebellar ataxia 27B?
Deep intronic FGF14 repeat expansions have been identified as a frequent genetic cause of late-onset cerebellar ataxias, explaining ≤30% of patients. Interruptions between repeats have previously been identified to impact the penetrance in other repeat expansion disorders. Repeat interruptions within FGF14 have yet to be characterized in detail. We used long-range PCR, Sanger sequencing, repeat-primed PCR, Nanopore and PacBio sequencing to distinguish the repeat motifs, mosaicism and number of repeat interruptions present in FGF14-related ataxia patients and unaffected individuals. A total of 304 patients with late-onset ataxia and 190 unaffected individuals were previously screened for repeat expansions in FGF14 by long-range PCR, identifying 37 individuals with expanded repeat lengths (≥250 repeats). These, along with three newly identified expansion carriers were included in the present study, and advanced genetic methods were applied to investigate the repeat composition in 27 patients and 13 unaffected individuals. The expansions, based on Nanopore data, ranged from 236 to 486 repeats (standard deviation = 60), with 20 individuals showing repeat interruptions, including complex motifs such as GAG, GAAGGA, GAAGAAAGAA, GAAAAGAAGAAGGAAGAAGGAA, GAAAAGAAGAAGGAA and GCAGAAGAAGAAGAA. We calculated the longest pure GAA length from the long-read data for all 40 individuals. When comparing the pure GAA tract between patients and unaffected individuals, clusters were apparent based on >200 or <200 repeats. Five ataxia patients with interruptions still had a remaining pure GAA expansion <200. We observed an association of the pure GAA length with age at onset (P = 0.016, R2 = 0.256). Somatically incurred mosaic divergent repeat interruptions were discovered that affect motif length and sequence (mDRILS), which varied in number and mosaicism (frequency: 0.37–0.93). The mDRILS were correlated with pure GAA length (P = 0.022, R2 = 0.334), with a higher mosaic frequency of interruptions in unaffected individuals compared with patients (unaffected: 0.90; patients: 0.67; P = 0.009). We demonstrate that: (i) long-read sequencing is required to detect complex repeat interruptions accurately; (ii) repeat interruptions in FGF14 are mosaic, have various lengths and start positions in the repeat tract, and can thereby be annotated as mDRILS; which (iii) enabled us to establish a categorization based on remaining pure GAA repeats quantifying the impact of mDRILS on pathogenicity or age at onset, dependent on the interruption length and position, with high accuracy; and (iv) we provide evidence that mosaicism stabilizes pure GAA repeats in interrupted FGF14 repeat expansions.